📰 Graybug Vision News
Graybug Vision News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Graybug Vision. Real-time updates on events, politics, business and more.
May 22, 2024
MorphoSys (NASDAQ:MOR – Get Free Report) and Graybug Vision (NASDAQ:GRAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Valuation & Earnings This table compares MorphoSys and Graybug […]
May 3, 2024
/PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in ophthalmic therapies, announced today the...
April 24, 2024
/PRNewswire/ -- DelveInsights Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices, Stargardt...
April 22, 2024
/PRNewswire/ -- DelveInsights Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...
April 9, 2024
/PRNewswire/ -- DelveInsights Corneal Edema Market Insights report includes a comprehensive understanding of current treatment practices, corneal edema...
February 22, 2024
This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
November 9, 2023
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
November 3, 2023
Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares dropped 2.3% during mid-day trading on Wednesday . The company traded as low as $2.15 and last traded at $2.15. Approximately 374 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 2,165 shares. The stock had previously closed at […]
October 23, 2023
The increasing diagnosed prevalence, and the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for RVO patients will drive the retinal vein occlusion market growth in the forecast period (2023–2032).New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed prevalence, and the development ...
October 23, 2023
New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed